Compare ADMA Biologics Inc (ADMA) vs ThredUp Inc (TDUP) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

TDUP trades at $6.84, down 2.7% today, with a consensus price target of $6.90. The stock shows bullish technical signals from moving averages, though oscillators are neutral. Recent Q1 2026 results met EPS expectations with record active buyers and 15% revenue growth. The company maintains a high gross margin of 79.4% but continues to report net losses, with improving cash flow from operations turning positive in 2025.

Investment outlook remains cautiously optimistic given analyst consensus (57% buy ratings) and recent business initiatives including AI integration and marketplace expansion. Key risks include persistent unprofitability and competitive pressures in resale markets. The stock presents potential for growth if margin improvements continue, but requires monitoring of earnings trajectory.